⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.
Lurasidone
لوراسیدون
🧠 Nervous SystemAtypical antipsychotic
🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Dangerous / avoid👴 Older adults:Dangerous / avoid 🇮🇷 Registered in Iran⛔ 1 contraindications⚠️ 1 interactions 🇺🇸 FDA approved (NDA) NDA200603ATC N05AE05
Market / country: 🇺🇸 USA
Latuda (US)
🧮 Dose calculator
Schizophrenia · Regimen source: FDA Latuda · 2.1
- • With food (at least 350 calories). FDA Latuda · 2.3
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to lurasidone; strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir…); strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St John’s wort…). FDA Latuda · 4
Warnings
- • Boxed warning: increased mortality in elderly patients with dementia-related psychosis. FDA Latuda · Boxed Warning
- • Boxed warning: increased suicidal thoughts and behaviour in children, adolescents and young adults. FDA Latuda · Boxed Warning
- • Neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes. FDA Latuda · 5
Important interactions
- • Moderate CYP3A4 inhibitor (e.g. diltiazem): halve the dose; start 20 mg, max 80 mg. FDA Latuda · 2
Renal adjustment
- • eGFR < 50: CrCl <50: start 20 mg, max 80 mg/day. FDA Latuda · 2.4
Formulations
- 20 mg tablet — tablet 🇺🇸 USA FDA Latuda · 3
- 40 mg tablet — tablet 🇺🇸 USA FDA Latuda · 3
- 60 mg tablet — tablet 🇺🇸 USA FDA Latuda · 3
- 80 mg tablet — tablet 🇺🇸 USA FDA Latuda · 3
- 120 mg tablet — tablet 🇺🇸 USA FDA Latuda · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Latuda · 8.1
“Risk Summary Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery [see Clinical Considerations ] .”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Latuda · 8.2
“Risk Summary Lactation studies have not been conducted to assess the presence of lurasidone in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Latuda · Boxed Warning
“Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients.”
- 👴 Older adultsDangerous / avoid
Label: serious warning or avoid in older adults. FDA Latuda · Boxed Warning
“WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA200603
- DailyMed (FDA label)FDA Latuda
- MedlinePlus (NIH)Lurasidone
- WHO ATC/DDDN05AE05
- Darooyab (Iran)Lurasidone
🇮🇷 Registered in Iran Darooyab · G-4770/Lurasidone
Dosage forms with Iranian generic codes, per Darooyab.
- 18904 · LURASIDONE 40MG TAB · قرص لوراسیدون ۴۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Latuda · 3FDA Latuda · 2.1FDA Latuda · 2.3FDA Latuda · 2.2FDA Latuda · 4FDA Latuda · Boxed WarningFDA Latuda · 5FDA Latuda · 2.4FDA Latuda · 2FDA Latuda · 8.1FDA Latuda · 8.2FDA Latuda · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4770/Lurasidone
- Clinical review⚠ Unverified